We are live on ! Find out more
FM

Frazier Management Portfolio holdings

AUM $1.12M
1-Year Est. Return 151.58%
This Fund
S&P 500
This Quarter Est. Return
+21.81%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$415M
AUM Growth
+$27.8M
Cap. Flow
+$5.22M
Cap. Flow %
1.26%
Top 10 Hldgs %
87.52%
Holding
17
New
–
Increased
3
Reduced
–
Closed
–
Avg Time Held
5.5 quarters
Top 10 Avg Time Held
6.3 quarters
Top 20 Avg Time Held
5.5 quarters

Top Buys

Rank Stock Value
1
KZR icon
Kezar Life Sciences
KZR
+$2.37M
2
ALPN icon
Alpine Immune Sciences Inc
ALPN
+$2.32M
3
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$533K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ANAB icon
1
AnaptysBio
ANAB
$1.36B
$169M 40.73%
2,316,447
– –
2017 Q1
8 quarters
KRYS icon
2
Krystal Biotech
KRYS
$9.51B
$28.8M 6.93%
875,000
– –
2018 Q3
2 quarters
COLL icon
3
Collegium Pharmaceutical
COLL
$701M
$28.6M 6.88%
1,887,332
– –
2015 Q4
13 quarters
GRTS icon
4
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$27.4M 6.6%
2,061,758
– –
2018 Q3
2 quarters
ALNA
5
DELISTED
Allena Pharmaceuticals
ALNA
$23.4M 5.63%
3,330,373
– –
2017 Q4
5 quarters
TPST icon
6
Tempest Therapeutics
TPST
$11.5M
$20.9M 5.04%
7,162
– –
2018 Q4
1 quarter
IOVA icon
7
Iovance Biotherapeutics
IOVA
$6.57B
$20.8M 5.01%
2,188,331
– –
2016 Q2
11 quarters
ALPN icon
8
DELISTED
Alpine Immune Sciences Inc
ALPN
$17.6M 4.25%
2,571,450
+372,439
+17% +$2.32M
2017 Q3
6 quarters
SRRA
9
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$13.9M 3.34%
202,803
– –
2015 Q4
13 quarters
APTX
10
DELISTED
Aptinyx Inc. Common Stock
APTX
$12.9M 3.11%
3,190,079
– –
2018 Q2
3 quarters
ITRM icon
11
DELISTED
Iterum Therapeutics
ITRM
$12.2M 2.93%
102,554
– –
2018 Q2
3 quarters
NBRV
12
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$10.4M 2.5%
17,026
+977
+6% +$533K
2018 Q3
2 quarters
ETTX
13
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$9.12M 2.2%
1,349,953
– –
2018 Q3
2 quarters
SYBX icon
14
DELISTED
Synlogic
SYBX
$6.57M 1.58%
57,694
– –
2018 Q1
4 quarters
KZR icon
15
DELISTED
Kezar Life Sciences
KZR
$6.57M 1.58%
37,008
+12,008
+48% +$2.37M
2018 Q2
3 quarters
BLCM
16
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$3.54M 0.85%
105,144
– –
2018 Q2
3 quarters
CDTX icon
17
DELISTED
Cidara Therapeutics
CDTX
$3.48M 0.84%
65,613
– –
2015 Q4
13 quarters

Similar funds

ACMV
August Capital Management VI Palo Alto, California $1.39M AUM
FRCMI
First Round Capital Management III Philadelphia, Pennsylvania $418K AUM
DB
DCVC Bio Palo Alto, California $313K AUM
NAM
Newfleet Asset Management Hartford, Connecticut $2.05M AUM 27.28% 1-Year Est. Return
AP
Atlas Principals Charlotte, North Carolina $2.19M AUM 56.71% 1-Year Est. Return
ID
Inspire Developers Forest Hills, New York $4.07M AUM
CI
CMT Investments Chicago, Illinois $5M AUM 15.27% 1-Year Est. Return
DIF
Discovery Investment Fund Singapore $6.98M AUM

Frazier Management's Q1 2019 Portfolio in Review

As of Q1 2019, Frazier Management held 17 positions worth $415M, up 7.2% from $388M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Trading was light in Q1 2019: portfolio turnover was 0%. Frazier Management opened no new positions and made no exits, leaving the 17-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Frazier Management added most to Kezar Life Sciences in Q1 2019, an estimated $2.37M increase.
  • Frazier Management's ten largest holdings make up 88% of its $415M portfolio in Q1 2019.
  • Frazier Management opened 0 new positions and closed 0 in Q1 2019.
  • Frazier Management's portfolio value rose 7.2% quarter-over-quarter to $415M.

Based on Frazier Management's 13F filing for Q1 2019, filed 15 May 2019.